



Ankle Arthroplasty – Single Service

Clinical Guidelines for Medical Necessity Review

Version: 1.0
Effective Date: September 7, 2023

Important Notices

Notices & Disclaimers:

GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2023 Cohere Health, Inc. All Rights Reserved.

Other Notices:

CPT copyright 2019 American Medical Association. All rights reserved.
CPT is a registered trademark of the American Medical Association.

Guideline Information:

Specialty Area: Diseases & Disorders of the Musculoskeletal System (M00-M99)
Guideline Name: Ankle Arthroplasty (Single Service)

Literature review current through: 9/7/2023

Document last updated: 9/7/2023

Type: ☒ Adult (18+ yo) | ☒ Pediatric (0-17yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	3
Service: Ankle Arthroplasty	3
General Guidelines	3
Medical Necessity Criteria	4
Indications	4
Non-Indications	5
Site of Service Criteria	6
Procedure Codes (HCPCS/CPT)	6
Medical Evidence	6
References	8

Medical Necessity Criteria

Service: Ankle Arthroplasty

General Guidelines

- **Units, Frequency, & Duration:** None.
- **Criteria for Subsequent Requests:** Repeat ankle arthroplasty may be indicated if previous surgery has failed due to implant failure, infection, incorrect positioning, or periprosthetic fracture.
- **Recommended Clinical Approach:** Ankle arthroplasty is a treatment for end-stage arthritis of the ankle using an FDA-approved artificial implant to replace a damaged ankle joint due to severe arthritis, arthrodesis of the contralateral ankle, or trauma. Physical therapy increases expected outcomes post-surgery including reduced pain and improved mobility, quality of life, and function.¹⁻²
- **Exclusions:** None.

Medical Necessity Criteria

Indications

- **Ankle Arthroplasty** is considered medically necessary when **ANY** of the following are **TRUE**¹⁻²⁰:
- ◆ The procedure is an initial ankle arthroplasty and **ALL** of the following are **TRUE**:
 - Degenerative joint disease is present with **ALL** of the following:
 - The patient requires treatment to improve **ONE** of the following:
 - ◆ Disabling pain; **OR**
 - ◆ Functional disability; **AND**
 - Imaging findings are consistent with arthritis of the ankle; **AND**
 - The patient has failed at least six months of conservative therapy including **ANY** of the following:
 - ◆ Anti-inflammatory medications; **OR**
 - ◆ Orthotic devices; **OR**
 - ◆ Activity modification; **OR**
 - ◆ Physical therapy); **AND**
 - The patient is not a candidate for joint preserving procedures; **AND**

- The patient is experiencing **ANY** of the following:
 - Moderate or severe pain that limits activities of daily living appropriate for the patient's age for a minimum of three months; **OR**
 - Reduction of mobility; **OR**
 - Affected ankle has a loss of function; **AND**
- The procedure involves **ONE** of the following FDA-approved devices:
 - Depuy Agility LP Total Ankle; **OR**
 - Paragon 28 Apex 3D Total Ankle Replacement System; **OR**
 - Integra Cadence Total Ankle System; **OR**
 - Kinetikos Eclipse Total Ankle Implant; **OR**
 - Wright INBONE Total Ankle System; **OR**
 - Wright INFINITY Total Ankle System; **OR**
 - Smith + Nephew Salto Talaris Total Ankle Prosthesis; **OR**
 - Wright INVISION Total Ankle Revision System; **OR**
 - Kinos Axiom Total Ankle Replacement System; **OR**
 - In2Bones Quantum Total Ankle; **OR**
 - Stryker Scandinavian Total Ankle Replacement (STAR) System; **OR**
 - Exactech Vantage Total Ankle System; **OR**
 - Zimmer Biomet Trabecular Metal Total Ankle; **AND**
- The provider educated the patient regarding other available treatments and their respective outcomes (e.g., joint debridement, distraction arthroplasty, osteotomy, arthrodesis); **OR**
- ◆ Revision ankle arthroplasty is considered medically necessary when previous surgery has failed due to **ANY** of the following:
 - Implant failure; **OR**
 - Infection; **OR**
 - Incorrect positioning; **OR**
 - Periprosthetic fracture; **OR**
 - Aseptic loosening

Non-Indications

→ **Ankle Arthroplasty** is not considered appropriate for patients with **ANY** of the following^{16,21-23}:

- ◆ Absence of the distal part of the fibula; **OR**
- ◆ Acute or chronic infection (with or without osteomyelitis or osteitis); **OR**
- ◆ Allergic reaction to metal; **OR**

- ◆ Circulatory disorders; **OR**
- ◆ Instability due to incompetent ligaments; **OR**
- ◆ Neuropathy (e.g., Charcot foot); **OR**
- ◆ Neuromuscular diseases; **OR**
- ◆ Osteonecrosis; **OR**
- ◆ Peripheral vascular disease; **OR**
- ◆ Poor bone quality (e.g., due to steroid treatment); **OR**
- ◆ Poor skin integrity due to scarring or trauma; **OR**
- ◆ Severe malalignment; **OR**
- ◆ Severe osteoporosis; **OR**
- ◆ Significant bone loss.

→ Ankle Arthroplasty may not be considered appropriate for patients with **ANY** of the following:

- ◆ Class III obesity defined as a body mass index [BMI] of 40 or higher or a BMI of 35 or higher for patients with obesity-related health conditions); **OR**
- ◆ Diabetes mellitus; **OR**
- ◆ Diabetic neuropathy; **OR**
- ◆ History of nicotine use; **OR**
- ◆ Ankle deformity (e.g. hindfoot, forefoot, knee); **OR**
- ◆ Ankle instability or lack of ligament support

Level of Care Criteria

Inpatient or Outpatient.

Procedure Codes (HCPCS/CPT)

HCPCS/CPT Codes	Code Description
C1776*	Joint device (implantable)
27700	Arthroplasty, ankle
27702*	Arthroplasty, ankle; with implant (total ankle)
27703*	Arthroplasty, ankle; revision, total ankle
27704	Removal of ankle implant
27870	Arthrodesis, ankle, open

* Experimental/investigational/unproven when used to report total ankle arthroplasty when combined with total talar prosthesis

Medical Evidence

Norvell et al. (2019) discuss a multisite prospective cohort on treatment methods for end-stage ankle arthritis. A total of 517 participants were included. Foot and Ankle Ability Measure (FAAM) activities of daily living and Short Form-36 (SF-36) scores were higher at 24 month follow-up among patients who underwent total ankle arthroplasty as compared to patients who underwent ankle arthrodesis. The authors conclude that both procedures are effective however, arthroplasty yields greater improved outcomes.¹⁶

National and Professional Organizations

The **American College of Foot and Ankle Surgeons (ACFAS)** published a position statement titled *Total Ankle Replacement Surgery*. Ankle fusion has been the long-standing treatment for end-stage ankle arthritis. The restriction of range of motion can put additional stress on adjacent joints thus the joints may also become arthritic. Ankle replacement techniques are more refined and offer an additional treatment option. While both procedures have comparable safety profiles, the ACFAS recommends ankle replacement over ankle fusion due to better patient function, pain relief, and quality of life.¹

The **American Orthopaedic Foot and Ankle Society (AOFAS)** published a position statement titled *The Use of Total Ankle Replacement for the Treatment of Arthritic Conditions of the Ankle*. While pain reduction is achieved with both ankle replacement and ankle arthrodesis, complication rates are higher following ankle replacement including the need for a secondary surgical procedure. Compared to ankle arthrodesis, ankle arthroplasty shows “marked improvement in quality of life, pain, and function”. Patients undergoing ankle arthroplasty report higher satisfaction with range of motion and gait when compared to ankle arthrodesis. Based on evidence in peer reviewed literature, the AOFAS supports ankle arthroplasty over ankle arthrodesis for the treatment of ankle arthritis when conservative management has failed.²

References

1. American College of Foot and Ankle Surgeons (ACFAS). Position statement: Total ankle replacement surgery. Approved February 2020. Accessed June 20, 2023.
<https://www.acfas.org/policy-advocacy/policy-position-statements/acfas-position-statement-total-ankle-replacement-surgery>.
2. American Orthopaedic Foot and Ankle Society (AOFAS). Position statement: The use of total ankle replacement for the treatment of arthritic conditions of the ankle. Approved July 29, 2022. Accessed June 20, 2023.
<https://www.aofas.org/research-policy/position-statements-clinical-guidelines>.
3. United States Food and Drug Administration (FDA). 510(k) premarket notification: Depuy Agility LP total ankle prosthesis. Decision Date October 31, 2012. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/CDRH510K/K120906.pdf>.
4. United States Food and Drug Administration (FDA). 510(k) premarket notification: Apex 3D total ankle replacement system. Decision Date March 6, 2021. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K210390>.
5. United States Food and Drug Administration (FDA). 510(k) premarket notification: Cadence total ankle system. Decision Date June 29, 2020. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K201507>.
6. United States Food and Drug Administration (FDA). 510(k) premarket notification: Eclipse total ankle. Decision Date November 22, 2006. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K061749>.
7. United States Food and Drug Administration (FDA). 510(k) premarket notification: The INBONE™ total ankle system, the INFINITY™ total ankle system and the INVISION™ total ankle revision system. Decision Date June 8, 2020. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K193067>.
8. United States Food and Drug Administration (FDA). 510(k) premarket notification: Integra Salto total ankle system. Decision Date December 18, 2018. Accessed June 21, 2023.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K182878>.

9. United States Food and Drug Administration (FDA). 510(k) premarket notification: Kinos Axiom total ankle system. Decision Date June 30, 2020. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192778>.
10. United States Food and Drug Administration (FDA). 510(k) premarket notification: Paragon 28 APEX 3D total ankle replacement system. Decision Date July 10, 2020. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192994>.
11. United States Food and Drug Administration (FDA). 510(k) premarket notification: Quantum® total ankle prosthesis. Decision Date January 29, 2020. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K191380>.
12. United States Food and Drug Administration (FDA). Premarket approval: Scandinavian total ankle replacement system (S.T.A.R. ankle). Decision Date May 27, 2009. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050050>.
13. United States Food and Drug Administration (FDA). 510(k) premarket notification: Vantage total ankle flat cut talar components. Decision Date April 1, 2019. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K183343>.
14. United States Food and Drug Administration (FDA). 510(k) summary: Zimmer trabecular metal total ankle. Published August 24, 2012. Accessed June 21, 2023.
<https://www.accessdata.fda.gov/CDRH510K/K120906.pdf>.
15. Murphy GA. Total ankle arthroplasty. In: Azar FM, Beatty JH, editors. Campbell's Operative Orthopaedics. 14th ed. Philadelphia, PA: Elsevier; 2021:526–562.e1.
16. Norvell DC, Ledoux WR, Shofer JB, et al. Effectiveness and safety of ankle arthrodesis versus arthroplasty: A prospective multicenter study. J Bone Joint Surg Am. 2019 Aug 21;101(16):1485–1494. doi: 10.2106/JBJS.18.01257. PMID: 31436657. PMCID: PMC7001770.

17. Taylor MA, Parekh SG. Optimizing outpatient total ankle replacement from clinic to pain management. *Orthop Clin North Am.* 2018 Oct;49(4):541–551. doi: 10.1016/j.ocl.2018.06.003. PMID: 30224015.
18. Yang HY, Wang SH, Lee KB. The HINTEGRA total ankle arthroplasty: Functional outcomes and implant survivorship in 210 osteoarthritic ankles at a mean of 6.4 years. *Bone Joint J.* 2019 Jun;101-B(6):695–701. doi: 10.1302/0301-620X.101B6.BJJ-2018-1578.R1. PMID: 31154845.
19. Yoon YK, Park KH, Park JH, et al. Long-term clinical outcomes and implant survivorship of 151 total ankle arthroplasties using the HINTEGRA prosthesis: A minimum 10-year follow-up. *J. Bone Joint Surg. Am.* 2022;104(16):1483–1491. doi: 10.2106/JBJS.22.00060.
20. Alajlan A, Valderrabano V. Joint preserving surgery for valgus ankle osteoarthritis. *Foot Ankle Clin.* 2022;27(1):57–72. doi: 10.1016/j.fcl.2021.11.003. PMID: 35219369.
21. Barg A, Wimmer MD, Wiewiorski M, et al. Total ankle replacement. *Dtsch Arztebl Int.* 2015;112(11):177–184. doi:10.3238/arztebl.2015.0177. PMID: 25837859. PMCID: PMC4390826.
22. van der Plaats LW, Haverkamp D. Patient selection for total ankle arthroplasty. *Orthop Res Rev.* 2017;9:63–73. doi:10.2147/ORR.S115411. PMID: 30774478. PMCID: PMC6209350.
23. Murphy GA. Total ankle arthroplasty. In: Azar FM, Beaty JH, editors. *Campbell's Operative Orthopaedics*. 14th ed. Philadelphia, PA: Elsevier; 2021:526–562.e1.

Clinical Guideline Revision History/Information

Original Date: September 7, 2023	
Review History	